- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Best Read Drug Coverage Stories in 2023
Express Scripts and Cigna Add Zepbound to Formularies
Zepbound was approved in November 2023 to treat patients with obesity. It was added to the national preferred formulary for Express Scripts and Cigna Healthcare in December.
Health Plans Release 2024 Prescription Changes in Medicare Plans
Aetna, Cigna, Humana, United Healthcare — some of the largest providers of Medicare Advantage plans — have released updates to prescription drug programs.
CVS Caremark Switches Up Biosimilar Coverage in 2024
New biosimilars have been added and others removed from CVS Caremark’s standard formulary. One notable change is with the Humira biosimilars. The PBM has removed Amjevita and now prefers Hyrimoz and an unbranded biosimilar.
Optum Rx Announces Formulary Exclusions for 2024
Optum Rx has added more than 50 products — including both branded and generics — to the exclusion list for the 2024 Premium Formulary.
CMS Expands Leqembi Coverage After FDA’s Full Approval
Medicare will cover Alzheimer’s drugs with full approval, including Leqembi — if the physician and patient participate in a real-world registry trial to gather additional data.
